USFDA Nod: Caplin Point Subsidiary Gets Final Approval For Acetaminophen Injection

Inside the announcement  
Caplin Steriles will now supply Acetaminophen Injection (1000 mg/100 mL, 10 mg/mL) in single-dose infusion bags, a widely used analgesic and antipyretic for pain management and fever reduction in hospital settings. The product is therapeutically equivalent to Mallinckrodt Pharmaceuticals’ reference drug. According to company disclosures, this approval validates Caplin’s R&D capabilities and strengthens its US portfolio of sterile injectables. Analysts project meaningful revenue potential from this launch, with estimates of US sales reaching $86 million annually.  

Notable updates  
• Caplin Steriles receives USFDA approval for Acetaminophen Injection ANDA  
• Product: 1000 mg/100 mL (10 mg/mL) single-dose infusion bags  
• Therapeutically equivalent to Mallinckrodt Pharmaceuticals’ reference drug  
• Approval enables entry into US hospital-use analgesic and antipyretic market  
• Analysts project US sales potential of ~$86 million annually  
• Strengthens Caplin’s sterile injectables portfolio and validates R&D capabilities  

Major takeaway  
The USFDA approval marks a significant milestone for Caplin Point Laboratories, enhancing its credibility in the regulated US market. By expanding its sterile injectables portfolio, the company is positioned to capture new growth opportunities in hospital-use therapeutics, reinforcing its global expansion strategy.  

Sources: Business Upturn, ScanX News